Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,945 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.
Kobayashi M, Narita S, Matsui Y, Kanda S, Hidaka Y, Abe H, Tsuzuki T, Ito K, Kojima T, Kato M, Hatakeyama S, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Morita S, Habuchi T, Ogawa O, Nishiyama H, Kitamura H, Kobayashi T; Japan Urological Oncology Group. Kobayashi M, et al. Among authors: hayashi t. BJU Int. 2022 Aug;130(2):226-234. doi: 10.1111/bju.15510. Epub 2021 Jul 6. BJU Int. 2022. PMID: 34110696
The impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in patients with metastatic renal cell carcinoma.
Teishima J, Kobatake K, Kitano H, Nagamatsu H, Sadahide K, Hieda K, Shinmei S, Shoji K, Inoue S, Hayashi T, Inoue Y, Ohara S, Mita K, Matsubara A. Teishima J, et al. Among authors: hayashi t. BJU Int. 2016 Jun;117(6B):E67-74. doi: 10.1111/bju.13260. Epub 2015 Sep 25. BJU Int. 2016. PMID: 26305535
Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab.
Kobayashi T, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Ogawa O, Kitamura H, Nishiyama H; Japan Urological Oncology Group. Kobayashi T, et al. Among authors: hayashi t. Cancer Sci. 2021 Feb;112(2):760-773. doi: 10.1111/cas.14762. Epub 2020 Dec 21. Cancer Sci. 2021. PMID: 33283385 Free PMC article.
Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.
Taoka R, Kobayashi T, Hidaka Y, Abe H, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Kamiyama M, Morita S, Ogawa O, Nishiyama H, Kitamura H, Sugimoto M; Japan Urological Oncology Group. Taoka R, et al. Among authors: hayashi t. Urol Oncol. 2022 Mar;40(3):107.e1-107.e9. doi: 10.1016/j.urolonc.2021.08.002. Epub 2021 Aug 26. Urol Oncol. 2022. PMID: 34454824
Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab.
Kato M, Kobayashi T, Matsui Y, Ito K, Hikami K, Yamada T, Ogawa K, Nakamura K, Sassa N, Yokomizo A, Abe T, Tsuchihashi K, Tatarano S, Inokuchi J, Tomida R, Fujiwara M, Takahashi A, Matsumoto K, Shimizu K, Araki H, Kurahashi R, Ozaki Y, Tashiro Y, Uegaki M, Kojima T, Uchida J, Ogawa O, Nishiyama H, Kitamura H; Japan Urological Oncology Group. Kato M, et al. Int J Urol. 2021 Dec;28(12):1261-1267. doi: 10.1111/iju.14686. Epub 2021 Sep 20. Int J Urol. 2021. PMID: 34545627
Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
Yukihiro K, Teishima J, Goto K, Aoki G, Sekino Y, Hayashi T, Hasegawa Y, Mita K, Kato M, Kajiwara M, Shigeta M, Maruyama S, Kadonishi Y, Fujiwara S, Hinata N. Yukihiro K, et al. Among authors: hayashi t. Urol Oncol. 2022 Oct;40(10):455.e11-455.e18. doi: 10.1016/j.urolonc.2022.06.016. Epub 2022 Jul 16. Urol Oncol. 2022. PMID: 35851184
9,945 results